

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
February 7, 2007
MINUTES

1. Call To Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, February 7, 2007.

2. Welcome

Dr. LaCroix called the meeting to order and welcomed members, guests, and staff members. It was announced that the newest member of the P&T Committee is Sara Lindsey, M.D.

Dr. LaCroix opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Gregory V. Browning, M.D.
Charmaine George, M.D.
Joe Horvath, M.D.
Kelly Jones, Pharm.D.

Robin K. LaCroix, M.D.
Jim Lindsay, M.D.
Sara Lindsey, M.D.
Tan Platt, M.D.

Deborah J. Tapley, R.Ph.
George E. Vess, Pharm. D.
Harry H. Wright, M.D.

DHHS Staff Present:

Marion Burton, M.D.
James M. Assey, R.Ph.
Wanda Metts
Byron Roberts, J.D.
Caroline Sojourner, R.Ph.

Other Representation:

First Health Services. – Mary Roberts, R.Ph.
Pharmaceutical Industry Representatives

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, November 1, 2006.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Presentation National Medicaid Pooling Initiative

Doug Brown, R.Ph., from First Health Services presented statistics and methodology regarding PDL management under the National Medicaid Pooling Initiative (NMPI).

C. Public Comment

The rules for public comment were outlined. Dr. LaCroix instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

Company	Speaker	Drug
Shire Pharmaceuticals	Bradford Loo, Pharm.D. National Medical Science Liaison Manager, Shire Pharmaceuticals	Fosrenol®
Abbott	Alan Neil Brown, M.D. Associate Professor of Medicine, MUSC Div of Rheumatology and Immunology President, S.C. Rheumatism Society	Humira®
Amgen	Ann Lyons, Pharm.D., BCPS Regional Medical Liaison Health Outcomes and Pharmacoeconomics, Amgen	Enbrel® Aranesp®
Inspire Pharmaceuticals	Charles Beischel, M.D., Ph.D. Private practice, Comprehensive Ophthalmology, Charleston, SC Certification, American Board of Ophthalmology	Elestat®
GlaxoSmithKline	Sherwana F. Clarke, Pharm.D. Senior Regional Medical Scientist, GlaxoSmithKline	Avandaryl®
Takeda Pharmaceuticals	J. Jay Van Horn, Pharm.D., MBA Senior Clinical and Outcomes Manager, Southeastern US, Takeda Pharmaceuticals	Duetact®
Allergan	H. Keith Riddle, Jr., M.D. Partner, Director of Laser Vision Correction & Cornea Service, Montgomery & Riddle Eyecare, P.A., Clinton SC Medical Director, The Surgery & Laser Center at Professional Park, Clinton SC Laser Surgen (Level 1), TLC Piedmont, Greenville, SC	Zymar®

D. Drug Classes for Re-Review

Mary Roberts, R.Ph., First Health Services Corporation, led the discussion for the following drug classes:

- Electrolyte Depleters
- Hematopoietic Agents
- Immunomodulators
- Ophthalmic Antihistamines
- Ophthalmic Quinolones
- Otic Quinolones
- Thiazolidinedione/Sulfonylurea Combinations

NO PA REQUIRED "PREFERRED"	PA REQUIRED
<i>Electrolyte Depleters</i>	
FOSRENOL® PHOSLO® RENAGEL®	
<i>Hematopoietic Agents</i>	
ARANESP® EPOGEN® PROCRIT®	
<i>Immunomodulators</i>	
ENBRELO® HUMIRA®	KINERET®
<i>Ophthalmic Antihistamines</i>	
PATANOL® PATADAY® ELESTAT®	EMADINE® KETOTIFEN FUMARATE OPTIVAR® ZADITOR® OTC
<i>Ophthalmic Quinolones</i>	
CIPROFLOXACIN HCL VIGAMOX® ZYMAR®	CILOXAN® OINTMENT OCUFLOX® DROPS OFLOXACIN DROPS QUIXIN®
<i>Otic Quinolones</i>	
CIPRODEX® FLOXIN OTIC®	CIPRO HC®
<i>Thiazolidinedione/Sulfonylurea Combinations</i>	
*AVANDARYL® *DUETACT®	
*PA required if a single agent thiazolidinedione or sulfonylurea product has not been prescribed previously.	

5. **Old Business**

6. **New Business**

A. PDL Savings, S .C. Medicaid Pharmacy Expenditures and Demographics

Mary Roberts, R.Ph. led a discussion regarding the S.C. Medicaid Pharmacy program demographics and expenditures and the impact the PDL has had on the program.

B. Physician Specialty Practices

There was discussion regarding the possibility of allowing physicians with certain practice specialties to be exempt from prior authorization requirements for PDL therapeutic classes related directly to their specialty areas.

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

Electrolyte Depleters
Hematopoietic Agents
Immunomodulators
Ophthalmic Antihistamines
Ophthalmic Quinolones
Otic Quinolones
Thiazolidinedione/Sulfonylurea Combinations

8. **Closing Comments**

The next meeting will be held on Wednesday, May 2, 2007 at 4:00 p.m. at the same location.

9. **Adjournment**

The meeting adjourned at 6:45 p.m.